Wellmarker Bio, the first spin-off company from Seoul Asan Medical Center, is developing anticancer drugs based on predictive biomarkers. Developing oncology treatments in parallel with predictive biomarkers enables researchers to predict the drugs’ efficacy. 

Link: https://news.mt.co.kr/mtview.php?no=2019102917202339020